Geoffrey Kim

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious <i>BRCA</i> Mutation–Associated Advanced Ovarian Cancer

Sanjeeve Balasubramaniam, Julia A. Beaver, Sara Horton et al. · Clinical Cancer Research · 2017 · 158 citations

FDA analysis of enrollment of older adults in clinical trials for cancer drug registration: A 10-year experience by the U.S. Food and Drug Administration.

Harpreet Singh, Bindu Kanapuru, Che Smith et al. · Journal of Clinical Oncology · 2017 · 154 citations

Geriatric Psychiatry, Cancer Management, Epidemiology Of Cancer +25

FDA Approval Summary: Nivolumab in Advanced Renal Cell Carcinoma After Anti-Angiogenic Therapy and Exploratory Predictive Biomarker Analysis

James Xu, V. Ellen Maher, Lijun Zhang et al. · The Oncologist · 2017 · 149 citations · Full text

Vandetanib for the Treatment of Symptomatic or Progressive Medullary Thyroid Cancer in Patients with Unresectable Locally Advanced or Metastatic Disease: U.S. Food and Drug Administration Drug Approval Summary

Katherine A. Thornton, Geoffrey Kim, V. Ellen Maher et al. · Clinical Cancer Research · 2012 · 147 citations

Caprelsa Tablets, U.s. Food, Medicine +11

FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer

Amanda J. Walker, Suparna Wedam, Laleh Amiri‐Kordestani et al. · Clinical Cancer Research · 2016 · 137 citations

Breast Oncology, Fda Approval, Pharmacotherapy +18